Business Description
Oragenics Inc
NAICS : 325412
SIC : 2834
ISIN : US6840236094
Total Employee Number:
3Description
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 109.05 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 5/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 72.8 | |||||
3-Year EPS without NRI Growth Rate | 72.3 | |||||
3-Year FCF Growth Rate | 73.5 | |||||
3-Year Book Growth Rate | -77.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 54.51 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.52 | |||||
9-Day RSI | 47.1 | |||||
14-Day RSI | 47.15 | |||||
3-1 Month Momentum % | 8.48 | |||||
6-1 Month Momentum % | -26.95 | |||||
12-1 Month Momentum % | -57.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.73 | |||||
Quick Ratio | 5.73 | |||||
Cash Ratio | 4.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -299.5 | |||||
Shareholder Yield % | 5.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -220.3 | |||||
ROA % | -135.46 | |||||
ROIC % | -757.95 | |||||
3-Year ROIIC % | -257.64 | |||||
ROC (Joel Greenblatt) % | -10049.2 | |||||
ROCE % | -210.61 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.41 | |||||
Price-to-Tangible-Book | 0.41 | |||||
EV-to-EBIT | 0.36 | |||||
EV-to-EBITDA | 0.36 | |||||
EV-to-FCF | 0.37 | |||||
| Price-to-Net-Current-Asset-Value | 0.41 | |||||
| Price-to-Net-Cash | 0.53 | |||||
Earnings Yield (Greenblatt) % | 277.78 | |||||
FCF Yield % | -353.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:OGEN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oragenics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.105 | ||
| Beta | 1.7038 | ||
| 3-Year Sharpe Ratio | -0.8 | ||
| 3-Year Sortino Ratio | -1.01 | ||
| Volatility % | 83.89 | ||
| 14-Day RSI | 47.15 | ||
| 14-Day ATR ($) | 0.034839 | ||
| 20-Day SMA ($) | 0.59506 | ||
| 12-1 Month Momentum % | -57.64 | ||
| 52-Week Range ($) | 0.5038 - 1.58 | ||
| Shares Outstanding (Mil) | 4.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oragenics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oragenics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 33 days | ||
| General meeting for 2025 | 2026-06-29 10:00 | 0.59 (+2.55%) | ||
| Sidoti\'s Micro-Cap Virtual Investor Conference | 2026-05-21 03:15 | 0.58 (+2.54%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 0.61 (-3.24%) | ||
| Annual report for 2025 | 2026-03-17 | 0.80 (-9.50%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 1.12 (-3.04%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 1.30 (+0.00%) | ||
| 0.0333333:1 Stock Split | 2025-06-03 | 5.01 (-38.15%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 5.40 (-5.26%) |
Show
Entries
Oragenics Inc Frequently Asked Questions
What is Oragenics Inc(OGEN)'s stock price today?
The current price of OGEN is $0.59. The 52 week high of OGEN is $1.58 and 52 week low is $0.50.
When is next earnings date of Oragenics Inc(OGEN)?
The next earnings date of Oragenics Inc(OGEN) is 2026-08-07 Est..
Does Oragenics Inc(OGEN) pay dividends? If so, how much?
Oragenics Inc(OGEN) does not pay dividend.
Guru Commentaries on AMEX:OGEN
No articles.
Press Release
Articles on Oragenics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers